The Department of Justice has named a private equity firm as a co-defendant in a False Claims Act complaint, along with one of its portfolio companies. DOJ alleges that the portfolio company paid illegal kickbacks related to compound drug prescriptions reimbursed by TRICARE in an effort to increase its ROI. The inclusion of a PE firm as a defendant could signal DOJ’s intention to hold private equity sponsors accountable for the noncompliance of their portfolio companies.
Regulations, Compliance, & Enforcement
Trending Now
New Bill Would Tighten Fraud Screening Across Federal Awards • US Department of Labor Announces 2026 Virtual Seminars for Current, Prospective Federal Contractors on Prevailing Wage Requirements • Grants Compliance 101: Your Grant Project Is Moving Forward. Now What? • FTC Signals Renewed “Made in USA” Enforcement Focus Following Trump Executive Order • The New DEI Crackdown: What Federal Contractors Must Do Now
DOJ Pursues PE Firm Based on Portfolio Company’s Alleged Payment of Kickbacks
Track False Claims Act cases, audit trends, and compliance best practices with our Compliance & Enforcement newsletter, delivering up-to-the-minute intelligence Monday–Saturday — Subscribe here.